Header Logo

Connection

Robert Mannel to Humans

Back to Details
This is a "connection" page, showing publications Robert Mannel has written about Humans.
Robert Mannel
Connection Strength
1.412
Humans
  1. What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (=10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer. Gynecol Oncol. 2022 09; 166(3):410-416.
    View in: PubMed
    Score: 0.045
  2. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. N Engl J Med. 2019 11 14; 381(20):1929-1939.
    View in: PubMed
    Score: 0.038
  3. Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients. Gynecol Oncol. 2019 08; 154(2):420-425.
    View in: PubMed
    Score: 0.037
  4. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2019 06 01; 37(16):1380-1390.
    View in: PubMed
    Score: 0.036
  5. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 06; 18(6):779-791.
    View in: PubMed
    Score: 0.032
  6. Is the NCI MATCH trial a match for gynecologic oncology? Gynecol Oncol. 2016 Jan; 140(1):161-6.
    View in: PubMed
    Score: 0.029
  7. Anti-angiogenic therapy versus dose-dense paclitaxel therapy for frontline treatment of epithelial ovarian cancer: review of phase III randomized clinical trials. Curr Oncol Rep. 2014 Nov; 16(11):412.
    View in: PubMed
    Score: 0.027
  8. Research: An event or an environment? Gynecol Oncol. 2014 Sep; 134(3):441-2.
    View in: PubMed
    Score: 0.026
  9. Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group. J Clin Oncol. 2014 Sep 01; 32(25):2744-9.
    View in: PubMed
    Score: 0.026
  10. A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2011 Jul; 122(1):89-94.
    View in: PubMed
    Score: 0.021
  11. A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2011 May 01; 121(2):264-8.
    View in: PubMed
    Score: 0.021
  12. A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol. 2010 Mar; 116(3):332-4.
    View in: PubMed
    Score: 0.019
  13. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Int J Gynecol Cancer. 2009 Jul; 19(5):929-33.
    View in: PubMed
    Score: 0.018
  14. Adjuvant chemotherapy for the "oldest old" ovarian cancer patients: can we anticipate toxicity-related treatment failure in a vulnerable population? Cancer. 2009 Apr 01; 115(7):1472-80.
    View in: PubMed
    Score: 0.018
  15. Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? Gynecol Oncol. 2008 Aug; 110(2):133-9.
    View in: PubMed
    Score: 0.017
  16. Uterine leiomyoma with associated pseudo-Meigs syndrome mimicking ovarian carcinoma. J Okla State Med Assoc. 2008 Feb; 101(2):38-9.
    View in: PubMed
    Score: 0.017
  17. Staffing for hospital lactation programs: recommendations from a tertiary care teaching hospital. J Hum Lact. 2006 Nov; 22(4):409-17.
    View in: PubMed
    Score: 0.015
  18. Carcinosarcoma of the ovary-a case series. Gynecol Oncol. 2006 Jan; 100(1):128-32.
    View in: PubMed
    Score: 0.014
  19. Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial. Nat Commun. 2025 Jan 09; 16(1):553.
    View in: PubMed
    Score: 0.014
  20. Gynecologic oncologists' perceptions of fellowship training. J Reprod Med. 2005 Jan; 50(1):29-34.
    View in: PubMed
    Score: 0.013
  21. Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer. Gynecol Oncol. 2004 Oct; 95(1):157-64.
    View in: PubMed
    Score: 0.013
  22. Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study. J Clin Oncol. 2024 Jul 20; 42(21):2537-2545.
    View in: PubMed
    Score: 0.013
  23. Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial. J Clin Oncol. 2024 Jul 10; 42(20):2425-2435.
    View in: PubMed
    Score: 0.013
  24. Developing a novel image marker to predict the clinical outcome of neoadjuvant chemotherapy (NACT) for ovarian cancer patients. Comput Biol Med. 2024 Apr; 172:108240.
    View in: PubMed
    Score: 0.013
  25. Impact of individual physicians on enrollment of patients into clinical trials. Am J Clin Oncol. 2003 Apr; 26(2):171-3.
    View in: PubMed
    Score: 0.012
  26. Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment Studies. J Clin Oncol. 2023 Apr 10; 41(11):2020-2028.
    View in: PubMed
    Score: 0.012
  27. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study. J Clin Oncol. 2022 Dec 01; 40(34):3965-3974.
    View in: PubMed
    Score: 0.012
  28. Ascites as a predictor of ovarian malignancy. Gynecol Oncol. 2002 Oct; 87(1):77-83.
    View in: PubMed
    Score: 0.012
  29. Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe. Gynecol Oncol. 2022 10; 167(1):3-10.
    View in: PubMed
    Score: 0.011
  30. A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium. Gynecol Oncol. 2022 07; 166(1):44-49.
    View in: PubMed
    Score: 0.011
  31. Recent advances and clinical applications of deep learning in medical image analysis. Med Image Anal. 2022 07; 79:102444.
    View in: PubMed
    Score: 0.011
  32. Laparoscopic pelvic and paraaortic lymph node dissection in the obese. Gynecol Oncol. 2002 Mar; 84(3):426-30.
    View in: PubMed
    Score: 0.011
  33. Surgical management of early-stage endometrial cancer in the elderly: is laparoscopy feasible? Gynecol Oncol. 2001 Dec; 83(3):563-8.
    View in: PubMed
    Score: 0.011
  34. Ovarian cancer metastatic to the brain: what is the optimal management? J Surg Oncol. 2001 Nov; 78(3):194-200; discussion 200-1.
    View in: PubMed
    Score: 0.011
  35. Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. J Natl Cancer Inst. 2021 10 01; 113(10):1369-1378.
    View in: PubMed
    Score: 0.011
  36. Laparoscopic pelvic and paraaortic lymph node dissection: analysis of the first 100 cases. Gynecol Oncol. 2001 Sep; 82(3):498-503.
    View in: PubMed
    Score: 0.011
  37. Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II. J Clin Oncol. 2021 11 10; 39(32):3623-3632.
    View in: PubMed
    Score: 0.011
  38. Predictors of complications after inguinal lymphadenectomy. Gynecol Oncol. 2001 Aug; 82(2):329-32.
    View in: PubMed
    Score: 0.011
  39. Nodal distribution and its significance in FIGO stage IIIc endometrial cancer. Gynecol Oncol. 2001 Aug; 82(2):375-9.
    View in: PubMed
    Score: 0.011
  40. A retrospective analysis of radical hysterectomies done for cervical cancer: is there a role for the Pfannenstiel incision? Gynecol Oncol. 2001 Jun; 81(3):481-4.
    View in: PubMed
    Score: 0.011
  41. Analysis of FIGO Stage IIIc endometrial cancer patients. Gynecol Oncol. 2001 May; 81(2):273-8.
    View in: PubMed
    Score: 0.010
  42. The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundation. Gynecol Oncol. 2021 07; 162(1):203-209.
    View in: PubMed
    Score: 0.010
  43. Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC). Gynecol Oncol. 2021 05; 161(2):382-388.
    View in: PubMed
    Score: 0.010
  44. Cisplatin and pentoxifylline in advanced or recurrent squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group. Gynecol Oncol. 2000 Oct; 79(1):64-6.
    View in: PubMed
    Score: 0.010
  45. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). J Clin Oncol. 2020 11 20; 38(33):3841-3850.
    View in: PubMed
    Score: 0.010
  46. What happened to the US cancer cooperative groups? A status update ten years after the Institute of Medicine report. Cancer. 2020 12 01; 126(23):5022-5029.
    View in: PubMed
    Score: 0.010
  47. Developing a new radiomics-based CT image marker to detect lymph node metastasis among cervical cancer patients. Comput Methods Programs Biomed. 2020 Dec; 197:105759.
    View in: PubMed
    Score: 0.010
  48. Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2020 10; 159(1):79-87.
    View in: PubMed
    Score: 0.010
  49. Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218. Clin Cancer Res. 2020 03 15; 26(6):1288-1296.
    View in: PubMed
    Score: 0.010
  50. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. J Clin Oncol. 2019 09 10; 37(26):2317-2328.
    View in: PubMed
    Score: 0.009
  51. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer. J Clin Oncol. 2019 07 20; 37(21):1810-1818.
    View in: PubMed
    Score: 0.009
  52. Current Activities of the Coalition of Cancer Cooperative Groups. J Natl Cancer Inst. 2019 01 01; 111(1):11-18.
    View in: PubMed
    Score: 0.009
  53. A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2019 03; 152(3):548-553.
    View in: PubMed
    Score: 0.009
  54. Prediction of chemotherapy response in ovarian cancer patients using a new clustered quantitative image marker. Phys Med Biol. 2018 08 06; 63(15):155020.
    View in: PubMed
    Score: 0.009
  55. Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study. Gynecol Oncol. 2018 08; 150(2):300-305.
    View in: PubMed
    Score: 0.009
  56. Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2018 06; 149(3):525-530.
    View in: PubMed
    Score: 0.008
  57. Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res. 2018 02 15; 24(4):777-783.
    View in: PubMed
    Score: 0.008
  58. Identification of Distant Metastatic Disease in Uterine Cervical and Endometrial Cancers with FDG PET/CT: Analysis from the ACRIN 6671/GOG 0233 Multicenter Trial. Radiology. 2018 04; 287(1):176-184.
    View in: PubMed
    Score: 0.008
  59. Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study. Br J Cancer. 2018 01; 118(2):162-170.
    View in: PubMed
    Score: 0.008
  60. Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses. J Natl Cancer Inst. 2017 11 01; 109(11).
    View in: PubMed
    Score: 0.008
  61. Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 12; 147(3):648-653.
    View in: PubMed
    Score: 0.008
  62. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol. 2017 11; 147(2):243-249.
    View in: PubMed
    Score: 0.008
  63. Applying Quantitative CT Image Feature Analysis to Predict Response of Ovarian Cancer Patients to Chemotherapy. Acad Radiol. 2017 10; 24(10):1233-1239.
    View in: PubMed
    Score: 0.008
  64. MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nat Commun. 2017 05 22; 8:14634.
    View in: PubMed
    Score: 0.008
  65. A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study. Ann Oncol. 2017 May 01; 28(5):996-1004.
    View in: PubMed
    Score: 0.008
  66. Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol. Gynecol Oncol. 2017 06; 145(3):519-525.
    View in: PubMed
    Score: 0.008
  67. FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 05; 145(2):366-373.
    View in: PubMed
    Score: 0.008
  68. A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852). Ann Oncol. 2017 03 01; 28(3):505-511.
    View in: PubMed
    Score: 0.008
  69. CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study. Clin Cancer Res. 2017 Jul 15; 23(14):3684-3691.
    View in: PubMed
    Score: 0.008
  70. A phase II trial of edatrexate in previously treated squamous cell cervical cancer: a Gynecologic Oncology Group study. Am J Clin Oncol. 1997 Feb; 20(1):78-80.
    View in: PubMed
    Score: 0.008
  71. Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 03; 144(3):459-467.
    View in: PubMed
    Score: 0.008
  72. Utility of PET/CT to Evaluate Retroperitoneal Lymph Node Metastasis in High-Risk Endometrial Cancer: Results of ACRIN 6671/GOG 0233 Trial. Radiology. 2017 05; 283(2):450-459.
    View in: PubMed
    Score: 0.008
  73. Synuclein-? in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. Cancer. 2017 04 01; 123(7):1144-1155.
    View in: PubMed
    Score: 0.008
  74. Effectiveness of cyanoacrylate microbial sealant in the reduction of surgical site infection in gynecologic oncology procedures: A phase III single institution prospective randomized trial. Gynecol Oncol. 2017 Jan; 144(1):193-199.
    View in: PubMed
    Score: 0.008
  75. Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis. Gynecol Oncol. 2016 Dec; 143(3):460-465.
    View in: PubMed
    Score: 0.008
  76. Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia. Obstet Gynecol. 2016 Sep; 128(3):535-542.
    View in: PubMed
    Score: 0.008
  77. Hepatic venoocclusive disease as a complication of whole abdominopelvic irradiation and treatment with the transjuglar intrahepatic portosystemic shunt: case report and literature review. Gynecol Oncol. 1996 May; 61(2):282-6.
    View in: PubMed
    Score: 0.007
  78. Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol. 2016 Apr; 2(4):482-90.
    View in: PubMed
    Score: 0.007
  79. Initiation of a formalized precision medicine program in gynecologic oncology. Gynecol Oncol. 2016 Apr; 141(1):24-8.
    View in: PubMed
    Score: 0.007
  80. Use of ileocecal continent urinary reservoir in patients with previous pelvic irradiation. Gynecol Oncol. 1995 Dec; 59(3):376-8.
    View in: PubMed
    Score: 0.007
  81. Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2015 Dec; 139(3):541-5.
    View in: PubMed
    Score: 0.007
  82. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Sep; 138(3):507-12.
    View in: PubMed
    Score: 0.007
  83. NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. Cancer. 2015 Jul 01; 121(13):2156-63.
    View in: PubMed
    Score: 0.007
  84. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 2015 Apr 01; 33(10):1180-5.
    View in: PubMed
    Score: 0.007
  85. Cost analysis of Hickman catheter insertion at bedside in gynecologic oncology patients. J Am Coll Surg. 1994 Nov; 179(5):558-60.
    View in: PubMed
    Score: 0.007
  86. Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study. Int J Gynecol Pathol. 2014 Nov; 33(6):543-53.
    View in: PubMed
    Score: 0.007
  87. SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm. Gynecol Oncol. 2014 Oct; 135(1):3-7.
    View in: PubMed
    Score: 0.007
  88. A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2014 Oct; 135(1):44-8.
    View in: PubMed
    Score: 0.007
  89. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2014 Oct; 135(1):38-43.
    View in: PubMed
    Score: 0.007
  90. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. Gynecol Oncol. 2014 Jan; 132(1):8-17.
    View in: PubMed
    Score: 0.006
  91. Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors. Gynecol Oncol. 2014 Jan; 132(1):50-4.
    View in: PubMed
    Score: 0.006
  92. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Jun; 129(3):486-94.
    View in: PubMed
    Score: 0.006
  93. A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr; 129(1):86-91.
    View in: PubMed
    Score: 0.006
  94. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013 Feb; 14(2):134-40.
    View in: PubMed
    Score: 0.006
  95. Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2013 Mar; 128(3):573-8.
    View in: PubMed
    Score: 0.006
  96. Hypogastric artery aneurysm masquerading as an ovarian neoplasm. Gynecol Oncol. 1992 Dec; 47(3):382-4.
    View in: PubMed
    Score: 0.006
  97. A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study. Gynecol Oncol. 2012 Dec; 127(3):456-61.
    View in: PubMed
    Score: 0.006
  98. A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Dec; 127(3):506-10.
    View in: PubMed
    Score: 0.006
  99. Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Oct; 127(1):70-4.
    View in: PubMed
    Score: 0.006
  100. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol. 2012 Mar 01; 30(7):695-700.
    View in: PubMed
    Score: 0.006
  101. Uterine serous carcinoma: increased familial risk for lynch-associated malignancies. Cancer Prev Res (Phila). 2012 Mar; 5(3):435-43.
    View in: PubMed
    Score: 0.005
  102. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011 Dec 29; 365(26):2473-83.
    View in: PubMed
    Score: 0.005
  103. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Apr; 125(1):54-8.
    View in: PubMed
    Score: 0.005
  104. Association of number of positive nodes and cervical stroma invasion with outcome of advanced endometrial cancer treated with chemotherapy or whole abdominal irradiation: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Apr; 125(1):87-93.
    View in: PubMed
    Score: 0.005
  105. Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma? Gynecol Oncol. 2012 Apr; 125(1):94-8.
    View in: PubMed
    Score: 0.005
  106. A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2012 Mar; 124(3):569-74.
    View in: PubMed
    Score: 0.005
  107. Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2011 Nov; 123(2):182-6.
    View in: PubMed
    Score: 0.005
  108. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol. 2011 Oct; 123(1):19-26.
    View in: PubMed
    Score: 0.005
  109. Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer. Gynecol Oncol. 2011 Sep; 122(3):527-31.
    View in: PubMed
    Score: 0.005
  110. First-line therapy in ovarian cancer trials. Int J Gynecol Cancer. 2011 May; 21(4):756-62.
    View in: PubMed
    Score: 0.005
  111. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol Oncol. 2011 Jun 01; 121(3):455-61.
    View in: PubMed
    Score: 0.005
  112. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol. 2011 Mar 01; 29(7):825-31.
    View in: PubMed
    Score: 0.005
  113. Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009. Int J Gynecol Cancer. 2010 Oct; 20(7):1290-8.
    View in: PubMed
    Score: 0.005
  114. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol. 2010 Dec; 119(3):444-50.
    View in: PubMed
    Score: 0.005
  115. A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2010 Sep; 118(3):303-7.
    View in: PubMed
    Score: 0.005
  116. Management of endometrial cancer with suspected cervical involvement. Obstet Gynecol. 1990 Jun; 75(6):1016-22.
    View in: PubMed
    Score: 0.005
  117. Indiana pouch continent urinary reservoir in patients with previous pelvic irradiation. Obstet Gynecol. 1990 May; 75(5):891-3.
    View in: PubMed
    Score: 0.005
  118. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J Clin Oncol. 2010 Jun 01; 28(16):2727-31.
    View in: PubMed
    Score: 0.005
  119. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol. 2009 Nov 10; 27(32):5331-6.
    View in: PubMed
    Score: 0.005
  120. Fixed-dose rate gemcitabine plus carboplatin in relapsed, platinum-sensitive ovarian cancer patients: results of a three-arm Phase I study. Gynecol Oncol. 2009 Dec; 115(3):389-95.
    View in: PubMed
    Score: 0.005
  121. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2009 Nov; 115(2):215-20.
    View in: PubMed
    Score: 0.005
  122. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol. 2009 Jun 01; 27(16):2686-91.
    View in: PubMed
    Score: 0.005
  123. Sequential chemotherapy and irradiation in advanced stage endometrial cancer: A Gynecologic Oncology Group phase I trial of doxorubicin-cisplatin followed by whole abdomen irradiation. Gynecol Oncol. 2009 Mar; 112(3):553-7.
    View in: PubMed
    Score: 0.004
  124. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group. Gynecol Oncol. 2008 Oct; 111(1):22-6.
    View in: PubMed
    Score: 0.004
  125. Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group. Gynecol Oncol. 2008 Sep; 110(3):329-35.
    View in: PubMed
    Score: 0.004
  126. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008 Jun; 109(3):329-34.
    View in: PubMed
    Score: 0.004
  127. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol. 2008 Mar; 108(3):493-9.
    View in: PubMed
    Score: 0.004
  128. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Oct 01; 25(28):4466-71.
    View in: PubMed
    Score: 0.004
  129. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007 Nov; 107(2):177-85.
    View in: PubMed
    Score: 0.004
  130. Treatment of ("bulky") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group. Gynecol Oncol. 2007 Aug; 106(2):362-9.
    View in: PubMed
    Score: 0.004
  131. Randomized trial results of quality of life comparing whole abdominal irradiation and combination chemotherapy in advanced endometrial carcinoma: A gynecologic oncology group study. Qual Life Res. 2007 Feb; 16(1):89-100.
    View in: PubMed
    Score: 0.004
  132. Human immunodeficiency virus testing in patients with invasive cervical carcinoma: a prospective trial of the gynecologic oncology group. Int J Gynecol Cancer. 2006 Mar-Apr; 16(2):660-3.
    View in: PubMed
    Score: 0.004
  133. Preoperative predictors of positive margins after loop electrosurgical excisional procedure-Cone. Gynecol Oncol. 2006 Feb; 100(2):379-84.
    View in: PubMed
    Score: 0.004
  134. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2006 Feb 01; 24(4):587-92.
    View in: PubMed
    Score: 0.004
  135. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2006 Jan 01; 24(1):36-44.
    View in: PubMed
    Score: 0.004
  136. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2006 Mar; 100(3):586-90.
    View in: PubMed
    Score: 0.004
  137. Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study. Gynecol Oncol. 2005 Oct; 99(1):71-9.
    View in: PubMed
    Score: 0.004
  138. Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study. Gynecol Oncol. 2005 Mar; 96(3):810-7.
    View in: PubMed
    Score: 0.003
  139. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol. 2005; 16 Suppl 8:viii7-viii12.
    View in: PubMed
    Score: 0.003
  140. A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference? Gynecol Oncol. 2004 Oct; 95(1):70-6.
    View in: PubMed
    Score: 0.003
  141. Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? Gynecol Oncol. 2004 Aug; 94(2):249-55.
    View in: PubMed
    Score: 0.003
  142. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Jan; 92(1):10-4.
    View in: PubMed
    Score: 0.003
  143. Outpatient implantation of a central venous access system in gynecologic oncology patients. J Reprod Med. 2003 Nov; 48(11):875-81.
    View in: PubMed
    Score: 0.003
  144. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003 Sep 01; 21(17):3194-200.
    View in: PubMed
    Score: 0.003
  145. Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2003 May; 89(2):267-70.
    View in: PubMed
    Score: 0.003
  146. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2002 Apr 01; 20(7):1832-7.
    View in: PubMed
    Score: 0.003
  147. Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2002 Jan 01; 52(1):14-22.
    View in: PubMed
    Score: 0.003
  148. Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study. Am J Clin Oncol. 2000 Aug; 23(4):355-7.
    View in: PubMed
    Score: 0.002
  149. Cost analysis of laparoscopy versus laparotomy for early endometrial cancer. Gynecol Oncol. 1999 Dec; 75(3):460-3.
    View in: PubMed
    Score: 0.002
  150. Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys. 1998 Dec 01; 42(5):1015-23.
    View in: PubMed
    Score: 0.002
  151. Laparoscopic paraaortic lymphadenectomy using laparosonic coagulating shears. J Am Assoc Gynecol Laparosc. 1998 Feb; 5(1):47-50.
    View in: PubMed
    Score: 0.002
  152. Primary endodermal sinus tumor of the vulva: a case report and review of the literature. Gynecol Oncol. 1997 Sep; 66(3):515-8.
    View in: PubMed
    Score: 0.002
  153. Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival. Gynecol Oncol. 1997 Jun; 65(3):425-9.
    View in: PubMed
    Score: 0.002
  154. P-glycoprotein as a prognostic indicator in pre- and postchemotherapy ovarian adenocarcinoma. Int J Gynecol Pathol. 1997 Jan; 16(1):69-75.
    View in: PubMed
    Score: 0.002
  155. Immunohistochemical assessment of proliferation markers and altered gene expression in archival specimens of ovarian epithelial tumors. Cancer Detect Prev. 1997; 21(6):532-9.
    View in: PubMed
    Score: 0.002
  156. Incidence and location of para-aortic lymph node metastases in gynecologic malignancies. J Am Coll Surg. 1995 Jul; 181(1):72-4.
    View in: PubMed
    Score: 0.002
  157. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol. 1994 Apr; 53(1):84-92.
    View in: PubMed
    Score: 0.002
  158. Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma. Cancer. 1994 Jan 15; 73(2):370-6.
    View in: PubMed
    Score: 0.002
  159. Comparison of clinical versus surgical staging systems in vulvar cancer. Obstet Gynecol. 1992 Dec; 80(6):927-30.
    View in: PubMed
    Score: 0.001
  160. Surgical treatment of unexpected invasive cervical cancer found at total hysterectomy. Obstet Gynecol. 1992 Dec; 80(6):931-4.
    View in: PubMed
    Score: 0.001
  161. Radiation myelitis: a complication of concurrent cisplatin and 5-fluorouracil chemotherapy with extended field radiotherapy for carcinoma of the uterine cervix. Gynecol Oncol. 1991 Dec; 43(3):305-8.
    View in: PubMed
    Score: 0.001
  162. Cellular fibroma masquerading as ovarian carcinoma. Obstet Gynecol. 1990 Sep; 76(3 Pt 2):530-1.
    View in: PubMed
    Score: 0.001
  163. Simplified postoperative patient-controlled analgesia on a gynecologic oncology service. Gynecol Oncol. 1990 Jul; 38(1):55-8.
    View in: PubMed
    Score: 0.001
  164. The influence of endometriosis on the staging of cervical cancer. Obstet Gynecol. 1990 Mar; 75(3 Pt 2):543-5.
    View in: PubMed
    Score: 0.001
  165. Treatment of advanced and recurrent endometrial carcinoma: correlation of patient response to hormonal and cytotoxic chemotherapy and the response predicted by the subrenal capsule chemosensitivity assay. Gynecol Oncol. 1989 Jan; 32(1):55-9.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.